Literature DB >> 12971811

Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation.

Lawrence A Labbate1, Harry A Croft, Marvin A Oleshansky.   

Abstract

The ideal antidepressant would control depression with no adverse effect on sexual function. Erectile dysfunction and other sexual dysfunction associated with antidepressant medication treatment are problems with many antidepressants and can lead to patient dissatisfaction and decreased compliance with treatment. A computerized MEDLINE search (English language, 1966-2003) was performed using the terms antidepressive agents, erectile dysfunction, and sexual dysfunction. Emphasis was placed on studies with specific sexual function measurements taken before and after treatment and placebo control. Mixed mediator, nonserotonergic antidepressants that block postsynaptic serotonin type 2 receptors (nefazodone, mirtazapine) or that primarily increase dopamine or norepinephrine levels (bupropion) were thought to be good choices for avoiding antidepressant-associated sexual dysfunction or for switching patients in whom antidepressant-associated sexual dysfunction emerged. Comparisons with serotonin reuptake inhibitors (SRIs) have revealed less desire and orgasm dysfunction with nonserotonergic bupropion, less orgasm dysfunction with nefazodone, and superior overall satisfaction with sexual functioning with bupropion or nefazodone. However, most of these studies have design flaws that make evidence-based claims of efficacy difficult to substantiate. Agents proposed for antidote use in antidepressant-associated sexual dysfunction have either not been studied in men or not proved efficacious in randomized placebo-controlled trials. Switching to and augmentation with bupropion or nefazodone have also not clearly shown efficacy in controlled trials and require care and monitoring to avoid SRI discontinuation symptoms and loss of antidepressant efficacy. Few proposed treatment options, apart from avoidance, have proved effective for antidepressant-associated sexual dysfunction, which can have negative consequences on depression management.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12971811

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

Review 1.  Prolactinergic and dopaminergic mechanisms underlying sexual arousal and orgasm in humans.

Authors:  Tillmann H C Krüger; Uwe Hartmann; Manfred Schedlowski
Journal:  World J Urol       Date:  2005-05-12       Impact factor: 4.226

2.  Pharmacotherapy of sexual dysfunctions : current status.

Authors:  Ajith Avasthi; Parthasarathy Biswas
Journal:  Indian J Psychiatry       Date:  2004-07       Impact factor: 1.759

3.  Lack of awareness of erectile dysfunction in many men with risk factors for erectile dysfunction.

Authors:  Ridwan Shabsigh; Joel Kaufman; Michelle Magee; Dana Creanga; David Russell; Meeta Budhwani
Journal:  BMC Urol       Date:  2010-11-05       Impact factor: 2.264

4.  Common prescription medication use and erectile dysfunction: results from the Boston Area Community Health (BACH) survey.

Authors:  Varant Kupelian; Susan A Hall; John B McKinlay
Journal:  BJU Int       Date:  2013-07-02       Impact factor: 5.588

5.  Antidepressant-associated sexual dysfunction: impact, effects, and treatment.

Authors:  Agnes Higgins; Michael Nash; Aileen M Lynch
Journal:  Drug Healthc Patient Saf       Date:  2010-09-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.